topotecan hydrochloride injection, powder, lyophilized, for solution
cipla usa inc. - topotecan hydrochloride (unii: 956s425zcy) (topotecan - unii:7m7ykx2n15) - topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (sclc) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of patients with stage iv-b, recurrent, or persistent cervical cancer of the cervix not amenable to curative treatment. topotecan hydrochloride for injection is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan. reactions have included anaphylactoid reactions [see adverse reactions (6.2)]. risk summary based on animal data and its mechanism of action, topotecan hydrochloride for injection can cause fetal harm when administe
topotecan hydrochloride injection, powder, lyophilized, for solution
actavis pharma, inc. - topotecan hydrochloride (unii: 956s425zcy) (topotecan - unii:7m7ykx2n15) - topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (sclc) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. topotecan hydrochloride for injection, in combination with cisplatin, is indicated for the treatment of patients with stage iv-b, recurrent, or persistent cervical cancer not amenable to curative treatment. topotecan hydrochloride is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan. reactions have included anaphylactoid reactions [see adverse reactions (6.2)]. risk summary based on animal data and its mechanism of action, topotecan hydrochloride can cause fetal harm when administered to a pregnant woman. there are no av
topotecan- topotecan hydrochloride injection, powder, lyophilized, for solution
meitheal pharmaceuticals inc. - topotecan hydrochloride (unii: 956s425zcy) (topotecan - unii:7m7ykx2n15) - topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (sclc) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. topotecan hydrochloride for injection, in combination with cisplatin, is indicated for the treatment of patients with stage iv-b, recurrent, or persistent cervical cancer not amenable to curative treatment. topotecan hydrochloride is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan. reactions have included anaphylactoid reactions [see adverse reactions (6.2)]. risk summary based on animal data and its mechanism of action, topotecan hydrochloride can cause fetal harm when administered to a pregnant woman. there are no av
topotecan accord healthcare 1 mg/ml inf. sol. (conc.) i.v. vial
accord healthcare b.v. - topotecan hydrochloride 1,0865 mg/ml - eq. topotecan 1 mg/ml - concentrate for solution for infusion - 1 mg/ml - topotecan hydrochloride - topotecan
topotecan accord healthcare 1 mg/ml inf. sol. (conc.) i.v. vial
accord healthcare b.v. - topotecan hydrochloride 1,0865 mg/ml - eq. topotecan 1 mg/ml - concentrate for solution for infusion - 1 mg/ml - topotecan hydrochloride - topotecan
hycamtin for injection 4 mgvial
novartis (singapore) pte ltd - topotecan hcl eqv topotecan - injection, powder, for solution - 4 mg/vial - topotecan hcl eqv topotecan 4 mg/vial
topotecan kabi
fresenius kabi australia pty limited - topotecan hydrochloride -
hycamtin
novartis new zealand ltd - topotecan hydrochloride 0.27mg equivalent to 0.25 mg topotecan - capsule - 0.25 mg - active: topotecan hydrochloride 0.27mg equivalent to 0.25 mg topotecan excipient: gelatin glyceryl monostearate hydrogenated vegetable oil tekprint black sw-9008 titanium dioxide - hycamtin capsules are indicated for the treatment of patients with relapsed small cell lung carcinoma (sclc).
hycamtin
novartis new zealand ltd - topotecan hydrochloride 1.24mg equivalent to 1.1 mg topotecan free base (incl. 10% overage) - powder for infusion - 1 mg - active: topotecan hydrochloride 1.24mg equivalent to 1.1 mg topotecan free base (incl. 10% overage) excipient: hydrochloric acid mannitol sodium hydroxide tartaric acid - hycamtin powder for infusion is indicated for: · monotherapy for the treatment of patients with: small cell lung carcinoma (sclc) after failure of first line chemotherapy metastatic carcinoma of the ovary after failure of first-line or subsequent therapy · combination therapy with cisplatin for the treatment of patients with histologically confirmed stage iv-b, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy
topotecan ag topotecan (as hydrochloride) 4 mg powder for injection vial
alphapharm pty ltd - topotecan hydrochloride, quantity: 4.346 mg - injection, powder for - excipient ingredients: sodium hydroxide; tartaric acid; hydrochloric acid; mannitol - topotecan ag for injection is indicated as single agent therapy for the treatment of patients with: - small cell lung carcinoma after failure of first line chemotherapy; - metastatic carcinoma of the ovary after failure of first-line or subsequent therapy. topotecan ag for injection is indicated in combination with cisplatin for the treatment of patients with: - histologically confirmed stage iv-b, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy.